However, despite encouraging early laboratory findings, its clinical development was discontinued in 2007 after failing to demonstrate significant weight-loss efficacy in large-scale human trials
According to the 2024 World Obesity Report, the global prevalence of obesity is steadily increasing, with projections indicating that by 2035, over half of the world's population will be classified as overweight [1]
If youre keeping an eye on your wallet, the 3-Cheese Chicken Flatbread is a budget-friendly option priced between $2.29 and $2.49
Pathophysiological targets for novel interventions The complex pathogenesis of SAH offers many targets for developing therapies, focusing on pathways that cause liver injury and complications
When used in patients experiencing lower GI symptoms while taking GLP-1 medications, ARM allows clinicians to: Differentiate between drug-related motility effects and true pelvic floor dysfunction Quantify the severity of anorectal dysfunction to support diagnosis and treatment planning Establish a baseline prior to initiating biofeedback or behavioral therapy Monitor progress if conservative management is pursued Persistent Constipation in GLP-1 Users ARM can determine if dyssynergic defecation is contributing to delayed evacuation, guiding appropriate therapy beyond simply adjusting medication
